High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

Table 5

Associations between liver metastasis and HD-TOR clinical benefit rate.

Study	Cases ()	Liver metastasis () (%)	ORR (%)	CBR (%)	Year	Reference
Retrospective	80	10 (12.5)	15.0	45.0	2010	Yamamoto et al. [12]
Retrospective	13	3 (23.0)	7.7	46.2	2012	Sawaki et al. [16]
Retrospective	21	2 (9.5)	21.1	63.2	2013	Koike et al. [13]
Prospective	46 (HD-TOR arm)	7 (15.2)	10.8	43.2	2013	Yamamoto et al. [14]
Retrospective	85	17 (20.0)	21.2	41.2	2014	Ishizuna et al. [15]
Retrospective	19	7 (36.8)	21.1	31.6	2019	This study

HD-TOR: high-dose toremifene; ORR: overall response rate; CBR: clinical benefit rate.